Article
Molecular determinants associated with resistance to imipenem and imipenem–relebactam in clinical Pseudomonas aeruginosa isolates
2025-11-04
Abstract excerpt
<title>Abstract</title> <p> Background <italic>Pseudomonas aeruginosa</italic> accounts for 10–20% of hospital-acquired infections and is a major pathogen in immunocompromised patients. Combination therapies with beta-lactam antibiotics and beta-lactamase inhibitors, such as imipenem-relebactam have improved treatment options, yet resistant strains have already emerged, with mechanisms still not fully elucidat...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 8501ed0f-1962-5adf-9bf6-b71bf6f2ef04
- DOI
- 10.21203/rs.3.rs-7801871/v1
